Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Ra Pharmaceuticals Inc (RARX)

$47.35 0.02 (0.04%)

16:24 EST RARX Stock Quote Delayed 15 Minutes

Volume:

Previous Close $47.33

Market Cap 1.53B

PE Ratio -18.79

EPS -2.52

Volume (Avg. Vol.) 625,142

Day's Range 47.26 - 47.48

52-Week Range 15.23 - 47.38

Dividend & Yield N/A (N/A)

RARX Stock Predictions, Articles, and Ra Pharmaceuticals Inc News

From InvestorPlace
From the Web

Ra Pharmaceuticals News: RARX Stock Flies 100% on $2.1 Billion UCB Deal

By William White, InvestorPlace Writer Oct 10, 2019

Ra Pharmaceuticals (NRARX) is seeing its stock take off on Thursday following news of a deal with UCB (UCBJF) valued at $2.10 billion.

5 Clinical-Stage Biotech Stocks to Buy

By Aaron Levitt, InvestorPlace Contributor Feb 25, 2019

There are plenty of potential in clinical-stage biotech stocks. Here are five with some wonderful catalysts.

5 Clinical-Stage Biotech Stocks to Buy Under $10

By Aaron Levitt, InvestorPlace Contributor May 29, 2018

Clinical-stage biotech stocks offer plenty of promise to investors looking to take on some risk. Here are five to buy today.

Stocks That Hit 52-Week Highs On Thursday

From Benzinga Dec 12, 2019

Thursday's morning session saw 348 companies set new 52-week highs. Noteworthy Mentions: Apple (NASDAQ: AAPL) was the largest company by market cap to set a new 52-week high...

The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

From Benzinga Dec 12, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (...

Stocks That Hit 52-Week Highs On Wednesday

From Benzinga Dec 11, 2019

Wednesday's morning session saw 173 companies set new 52-week highs. Noteables: Apple (NASDAQ: AAPL) was the company with the largest market cap to set a new 52-week high....

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

From Zacks Investment Research Dec 5, 2019

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

Ra Pharma commences mid-stage study of zilucoplan in rare type of myopathy

From Seeking Alpha Dec 4, 2019

Dosing is underway in a 24-subject Phase 2 clinical trial evaluating Ra Pharmaceuticals' (NASDAQ:RARX) zilucoplan for the treatment of immune-mediated necrotizing myopathy, a rare type of idiopathic (

Ra Pharmaceuticals EPS misses by $0.05, beats on revenue

From Seeking Alpha Nov 7, 2019

Ra Pharmaceuticals (NASDAQ:RARX): Q3 GAAP EPS of -$0.55 misses by $0.05.Revenue of $3M beats by $2.62M.Press Release

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy